Book of Abstracts – HUMANITAS Global Congress of Flourishing

Effects of Cannabidiol (CBD) on Depression, Anxiety, and Life Satisfaction in Parkinson’s Disease: A Randomized, Double-Blind, Open-Label Trial

Authors:
Aleksandra Ćwiklińska, Neurology Student Scientific Association NEKON, Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland
Olga Stodulska, Neurology Student Scientific Association NEKON, Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland
Kamila Kopeć, Neurology Student Scientific Association NEKON, Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland
Joanna Samborska, Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland
Sandra Laskowska, Institute of Psychology, Cardinal Stefan Wyszynski University, Warsaw, Poland
Dariusz Koziorowski, Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland
Aneta Brzezicka, Department of Psychology, SWPS University of Social Sciences and Humanities, Warsaw, Poland
Alicja Binkowska, Institute of Psychology, Humanitas University, Sosnowiec, Poland
Stanisław Szlufik, Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland

Abstract ID: 111

Keywords: Anxiety, CBD, Depression, Life Satisfaction, Open-Label Trial, Parkinson’s Disease

Background: Depression and anxiety are common non-motor symptoms in Parkinson’s disease. Cannabidiol (CBD), a non-intoxicating cannabis compound, has shown potential anxiolytic and antidepressant properties. This study evaluated the effectiveness of full-spectrum CBD oil on mood symptoms and life satisfaction in individuals with Parkinson’s disease.

Methods: In a randomized, double-blind trial, 25 participants with Parkinson’s disease completed the intervention. They were randomly assigned to one of three dosage groups: 30 mg/day (0.5 ml, n = 8), 60 mg/day (0.9 ml, n = 8), or 300 mg/day (4.5 ml, n = 9) of full-spectrum hemp-derived CBD oil, taken twice daily with meals. Assessments occurred weekly for four weeks using the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and Satisfaction With Life Scale (SWLS).

Results: Baseline demographic and clinical variables did not differ significantly between groups (all p > .05). Mixed-design ANOVAs showed no significant main effects of dosage or dosage-by-time interactions on BDI, BAI, or SWLS scores (all p > .50). However, significant main effects of time were found for BDI and BAI (both p < .001), with the greatest reductions between baseline and Week 1. SWLS scores remained stable across time and groups.

Conclusion: Full-spectrum CBD oil was associated with significant reductions in depression and anxiety symptoms, regardless of dosage. No changes in life satisfaction were observed. These findings suggest mood-related benefits of CBD in Parkinson’s disease, warranting further study in larger trials.

⇐ BACK